ArticleCrohn's & colitis 3602021

Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.

Bruce R Yacyshyn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.